Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 1/20 | 0.33 |
| ▸ | MMP3 | P08254 | 1/20 | 0.33 |
| ▸ | MMP8 | P22894 | 1/20 | 0.33 |
| ▸ | ANPEP | P15144 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26973342 | 0.78 | SMN1; SMN2 (0.33) | MMP2MMP8 | |
| SCHEMBL19961862 | 0.77 | CYP2D6 (0.30) | — | |
| SCHEMBL20333341 | 0.77 | MMP2 (0.37) | MMP2MMP3MMP8ANPEP | |
| SCHEMBL13484759 | 0.75 | FDPS (0.32) | ANPEP | |
| SCHEMBL24836139 | 0.73 | MMP2 (0.34) | MMP2MMP3MMP8 | |
| SCHEMBL26973341 | 0.71 | CYP2C9 (0.44) | MMP8 | |
| SCHEMBL19010455 | 0.70 | ADAM17 (0.31) | MMP2MMP3MMP8 | |
| SCHEMBL27325203 | 0.68 | — | — | |
| SCHEMBL24983189 | 0.67 | MEN1 (0.31) | — | |
| SCHEMBL9811847 | 0.66 | MMP8 (0.43) | MMP2MMP3MMP8ANPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11034715-B2 | Ectonucleotidase inhibitors and methods of use thereof | CALITHERA BIOSCIENCES, INC. (US) | 2021-06-15 | — | — | US | disclosed |
| US-20200223882-A1 | Ectonucleotidase Inhibitors and Methods of Use Thereof | ANTENGENE THERAPEUTICS LIMITED (CN) | 2020-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200223882-A1 | Ectonucleotidase Inhibitors and Methods of Use Thereof | NT5E, ENTPD5, NT5C2 | MMP2 743/4885MMP3 503/4885MMP8 214/4885 |
| US-11034715-B2 | Ectonucleotidase inhibitors and methods of use thereof | NT5E, ENTPD5, NT5C2 | MMP2 743/4885MMP3 503/4885MMP8 214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.